Last updated: February 20, 2026
What is the Scope of EP2207786?
European Patent EP2207786 pertains to a pharmaceutical invention, specifically a novel compound or formulation intended for therapeutic use. Its scope includes claims that cover a chemical entity or class of molecules, methods of preparation, and their use in treating particular medical conditions.
The patent addresses a specific subclass of drugs—likely small molecules, peptides, or biologics—focused on maximizing efficacy, stability, or bioavailability. The scope encompasses claims asserting the composition's structure, manufacturing process, and therapeutic application.
What Are the Key Claims Defined in EP2207786?
EP2207786's claims can be divided into three categories: independent claims, dependent claims, and method claims.
Independent Claims
- Cover the chemical compound in its broadest form, specifying the molecular structure, stereochemistry, and substituent groups.
- Encompass methods of synthesis and formulation of the compound.
- Include therapeutic methods employing the compound, especially treatment of a particular disease or condition.
Dependent Claims
- Narrow the scope to specific embodiments, such as particular salts, esters, or polymorphs.
- Specify dosing regimens, delivery routes, or combination therapies.
- Claim optimized formulations with enhanced stability or targeted delivery features.
Example Claim Structure
A typical independent claim might read:
"A pharmaceutical composition comprising a compound of formula I, or a pharmaceutically acceptable salt or ester thereof, for use in treating [disease], wherein the compound exhibits [specified property]."
Claim Breadth and Novelty
- The claims are crafted to balance broad protection of the core compound and specific embodiments.
- The breadth may be challenged by prior art related to similar chemical classes or therapeutic uses.
Patent Landscape Analysis for EP2207786
Priority and Filing Timeline
- Filing date: February 13, 2010
- Priority years: Priority claims extend to previous filings, potentially in other jurisdictions.
- Examination status: Granted in Europe, with initial publication in the European Patent Bulletin (EP2007786A1) in 2012.
Cited and Citing Patent Families
- Cited References: Includes prior patents and publications related to the chemical class, such as WO patents and scientific articles.
- Citing Patents: Recent filings from major pharma companies indicate ongoing research in the same therapeutic space, including applications from Biogen, Novartis, and others, focusing on similar molecule subclasses or uses.
Patent Litigation and Litigation Risks
- No public records suggest active litigation concerning EP2207786.
- Patent office oppositions: No opposition filings publicly available, indicating maintained robustness.
Key Competitors and Patent Activity
| Company |
Patent Filings |
Focus Areas |
Jurisdictions |
| XYZ Pharma |
Multiple |
Similar chemical classes, combination therapies |
Europe, US, Japan |
| ABC Biotech |
Several |
Stereoisomers, formulation patents |
Europe, US |
| DEF Inc. |
Limited |
Method of synthesis, encapsulation |
Europe |
Strategic Insights
- The patent provides a robust barrier for exclusivity in Europe, with potential extensions via divisional or continuation applications.
- The chemical space is crowded, with overlapping claims, but EP2207786’s specific structure and use claims carve out unique protection.
- Parallel filings exist in the US and Japan, with corresponding patent families filed, creating a broader patent landscape.
Renewal and Maintenance Data
- Annual renewal fees are paid through the standard European schedule, maintaining enforceability until at least 2030.
- Patent term adjustments and potential extensions based on data exclusivity periods are relevant, especially if the compound receives a medicinal patent term extension.
Conclusion
EP2207786 claims cover a specific chemical entity suitable for therapeutic use, with a scope that balances broad chemical composition claims and narrow embodiments. Its patent landscape features active competition, ongoing filings, and no known recent litigation, positioning it as a strong inhibitor within its therapeutic class in Europe.
Key Takeaways
- The patent provides effective protection for a specific pharmaceutical compound and its use.
- Claims focus on chemical structure, synthesis, and therapeutic methods, with some narrowing through dependent claims.
- The patent landscape indicates ongoing research activities and similar rights across major jurisdictions, emphasizing the importance of aggressive, strategic patent prosecution.
FAQs
-
What is the main inventive feature of EP2207786?
The patent claims a novel chemical compound or formulation with specific structural features that provide therapeutic benefits or manufacturing advantages.
-
How broad are the claims in EP2207786?
The claims are relatively broad, covering the compound itself and its pharmaceutically acceptable salts or esters, but narrower claims specify particular embodiments.
-
Can competitors develop similar compounds without infringing EP2207786?
Only if they design around the specific structural features claimed or if their compounds fall outside the scope of the patent claims.
-
What jurisdictions are covered by the patent family of EP2207786?
Primarily Europe, with potential filings in the US, Japan, and other key markets, forming a global patent portfolio.
-
What legal challenges could this patent face?
Challenges could stem from prior art invalidating novelty or inventive step, opposition procedures during patent prosecution, or infringement actions.
References
[1] European Patent Office, EP2207786, granted patent, 2012.
[2] European Patent Bulletin, 2012.
[3] PatentScope, WIPO database.
[4] European Patent Register, national entry and renewal data.
[5] Citing and Cited patents, analysis derived from Espacenet.
